GENFIT: Historic Milestone Achieved with U.S. FDA Accelerate

GENFIT: Historic Milestone Achieved with U.S. FDA Accelerated Approval of Ipsen's Iqirvo® for Primary Biliary Cholangitis

GENFIT: Historic Milestone Achieved with U.S. FDA Accelerated Approval of Ipsen's Iqirvo® for Primary Biliary Cholangitis
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

China , United Kingdom , Paris , France General , France , Macau , Cambridge , Cambridgeshire , Massachusetts , United States , Switzerland , Hong Kong , Taiwan , American , Stephanie Boyer , Pascal Prigent , Ipsen Iqirvo , Ipsen Euronext , Newborn Development , Drug Administration , Nasdaq , Euronext , European Medicines Agency , Regulatory Agency , Terns Pharmaceuticals , Ipsen Pharmaceuticals , Ipsen Pharmaceuticals Inc , Exchange Commission , Primary Biliary Cholangitis , Chronic Liver Failure , Induced Liver Injury , Adverse Event , Reproductive Potential , Breakthrough Therapy Designation , United Kingdom Medicines , New England Journal , Acute On Chronic Liver Failure , Nasdaq Global Select Market , Rare Disease , Sponsored Leveli American Depositary Receipt , Private Securities Litigation Reform Act , Registration Document , Primary Biliary , Historic Milestone Achieved ,